[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. [2] Kawazoe A, Fukuoka S, Nakamura Y, et al.Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(8): 1057-1065. [3] Pilleron S, Sarfati D, Janssen-Heijnen M, et al.Global cancer incidence in older adults, 2012 and 2035: A population-based study[J]. Int J Cancer, 2019, 144(1): 49-58. [4] Hydbring P, Wang Y, Fassl A, et al.Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers[J]. Cancer Cell, 2017, 31(4): 576-590. [5] Cai Y, Yu X, Hu S, et al.A brief review on the mechanisms of miRNA regulation[J]. Genomics Proteomics Bioinformatics, 2009, 7(4): 147-154. [6] Cheng J, Zhuo H, Xu M, et al.Regulatory network of circRNA-miRNA-mRNA contributes to the histological classification and disease progression in gastric cancer[J]. J Transl Med, 2018, 16(1): 216. [7] Yang Y, Qu A, Zhao R, et al.Genome-wide identification of a novel miRNA-based signature to predict recurrence in patients with gastric cancer[J]. Mol Oncol, 2018, 12(12): 2072-2084. [8] Meng H, Li YY, Han D, et al.MiRNA-93-5p promotes the biological progression of gastric cancer cells via Hippo signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2019, 23(11): 4763-4769. [9] Li L, Zhao J, Huang S, et al.MiR-93-5p promotes gastric cancer-cell progression via inactivation of the Hippo signaling pathway[J]. Gene, 2018, 641: 240-247. [10] Wang H, Gou X, Jiang T, et al.The effects of microRNAs on glucocorticoid responsiveness[J]. J Cancer Res Clin Oncol, 2017, 143(6): 1005-1011. [11] Zhou D, Li X, Zhao H, et al.Combining multi-dimensional data to identify a key signature (gene and miRNA) of cisplatin-resistant gastric cancer[J]. J Cell Biochem, 2018, 119(8): 6997-7008. [12] Stein U, Walther W, Arlt F, et al.MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis[J]. Nat Med, 2009, 15(1): 59-67. [13] Dahlmann M, Werner R, Kortum B, et al.Restoring Treatment Response in Colorectal Cancer Cells by Targeting MACC1-Dependent ABCB1 Expression in Combination Therapy[J]. Front Oncol, 2020, 10: 599. [14] Budczies J, Kluck K, Walther W, et al.Decoding and targeting the molecular basis of MACC1-driven metastatic spread: Lessons from big data mining and clinical-experimental approaches[J]. Semin Cancer Biol, 2020, 60: 365-379. [15] Zheng D, Che D, Lin F, et al.LncRNA MACC1-AS1/MACC1 enhances the progression of glioma via regulating metabolic plasticity[J]. Cell Cycle, 2020, 19(18): 2286-2297. [16] Mao W, Li T.LncRNA MACC1-AS1 Promotes Lung Adenocarcinoma Cell Proliferation by Downregulating PTEN[J]. Cancer Biother Radiopharm, 2020, 35(4): 313-318. [17] Makino T, Orita Y, Gion Y, et al.MACC1 expression is an indicator of recurrence in early-stage glottic cancer[J]. Jpn J Clin Oncol, 2020, 50(4): 392-398. [18] Tong H, Liu X, Li T, et al.MACC1-AS1 promotes hepatocellular carcinoma cell invasion and proliferation by regulating PAX8[J]. Aging (Albany NY), 2020, 12(1): 70-79. [19] Zheng G, You C, Qiu Z, et al.Expression of MACC1 protein in gastric cancer and its effect on proliferation and invasion of gastric cancer cells[J]. Cell Mol Biol (Noisy-le-grand), 2020, 66(2): 111-117. [20] Xie QP, Xiang C, Wang G, et al.MACC1 upregulation promotes gastric cancer tumor cell metastasis and predicts a poor prognosis[J]. J Zhejiang Univ Sci B, 2016, 17(5): 361-366. [21] Hwang J, Min BH, Jang J, et al.MicroRNA Expression Profiles in Gastric Carcinogenesis[J]. Sci Rep, 2018, 8(1): 14393. [22] Shen Y, Chen H, Gao L, et al.MiR-638 acts as a tumor suppressor gene in gastric cancer[J]. Oncotarget, 2017, 8(64): 108170-108180. [23] Lin L, Liu Y, Pan C, et al.Gastric cancer cells escape metabolic stress via the DLC3/MACC1 axis[J]. Theranostics, 2019, 9(7): 2100-2114. [24] Tong G, Cheng B, Li J, et al.MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells[J]. Cancer Med, 2019, 8(16): 7044-7054. |